Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue

In classical Hodgkin Lymphoma (cHL), immunoediting via protein signaling is key to evading tumor surveillance. We aimed to identify immune-related proteins that distinguish diagnostic cHL tissues (=diagnostic tumor lysates, = 27) from control tissues (reactive lymph node lysates, = 30). Further, we...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-01, Vol.14 (1), p.9
Main Authors: Gholiha, Alex Reza, Hollander, Peter, Löf, Liza, Larsson, Anders, Hashemi, Jamileh, Ulfstedt, Johan Mattsson, Molin, Daniel, Amini, Rose-Marie, Freyhult, Eva, Kamali-Moghaddam, Masood, Enblad, Gunilla
Format: Article
Language:English
Subjects:
Algorithms
Biobanks
Biomarkers
Biopsy
Cancer
Cancer immunotherapy
CCL17 protein
CCL3 protein
Epstein-Barr virus
Gender
Gene expression
Hodgkin's lymphoma
Interleukin 13
Interleukin 6
Lymph nodes
Lymphatic system
Lymphoma
Lysates
Patients
PD-L1 protein
Plasma
Precision medicine
Proteins
Proteomes
Proteomics
Regression analysis
Therapeutic targets
Tumor microenvironment
Tumors
γ-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In classical Hodgkin Lymphoma (cHL), immunoediting via protein signaling is key to evading tumor surveillance. We aimed to identify immune-related proteins that distinguish diagnostic cHL tissues (=diagnostic tumor lysates, = 27) from control tissues (reactive lymph node lysates, = 30). Further, we correlated our findings with the proteome plasma profile between cHL patients ( = 26) and healthy controls ( = 27). We used the proximity extension assay (PEA) with the OlinkTM multiplex Immuno-Oncology panel, consisting of 92 proteins. Univariate, multivariate-adjusted analysis and Benjamini-Hochberg's false discovery testing (=Padj) were performed to detect significant discrepancies. Proteins distinguishing cHL cases from controls were more numerous in plasma (30 proteins) than tissue (17 proteins), all Padj < 0.05. Eight of the identified proteins in cHL tissue (PD-L1, IL-6, CCL17, CCL3, IL-13, MMP12, TNFRS4, and LAG3) were elevated in both cHL tissues and cHL plasma compared with control samples. Six proteins distinguishing cHL tissues from controls tissues were significantly correlated to PD-L1 expression in cHL tissue (IL-6, MCP-2, CCL3, CCL4, GZMB, and IFN-gamma, all ≤0.05). In conclusion, this study introduces a distinguishing proteomic profile in cHL tissue and potential immune-related markers of pathophysiological relevance.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14010009